Markets:

Overview

News

Currencies

International

Treasuries

IMV Inc. - Common Shares (NQ:IMV)

N/A UNCHANGED

Last Price Updated: 3:58 PM EDT, Apr 28, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about IMV Inc. - Common Shares

< Previous 1 2 3 4 5 Next >

Recap: IMV Q4 Earnings ↗

March 17, 2022

IMV (NASDAQ:IMV) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings IMV...

Via Benzinga

IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results

March 17, 2022

From IMV Inc.

Via Business Wire

Earnings Scheduled For March 17, 2022 ↗

March 17, 2022

Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is...

Via Benzinga

Earnings Preview For IMV ↗

March 16, 2022

IMV (NASDAQ:IMV) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗

March 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Earnings Scheduled For November 11, 2021 ↗

November 11, 2021

Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape...

Via Benzinga

IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform

February 17, 2022

From IMV Inc.

Via Business Wire

The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award ↗

January 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen...

Via Benzinga

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

January 12, 2022

From IMV Inc.

Via Business Wire

IMV Inc. to Present at Two Upcoming Investor Events

January 05, 2022

From IMV Inc.

Via Business Wire

IMV Appoints Andrew Hall as Chief Executive Officer

December 22, 2021

From IMV Inc.

Via Business Wire

IMV's Basket Clinical Study Shows Promising Top Line Data In Bladder Cancer ↗

December 21, 2021

IMV Inc (NASDAQ: IMV) announced the finalization of the basket clinical study evaluating maveropepimut-S (MVP-S) in combination with Merck & Co Inc's...

Via Benzinga

IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

December 21, 2021

From IMV Inc.

Via Business Wire

IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility

December 20, 2021

From IMV Inc.

Via Business Wire

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO ↗

December 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug...

Via Benzinga

Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress

December 02, 2021

From IMV Inc.

Via Business Wire

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

November 30, 2021

From IMV Inc.

Via Business Wire

IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference

November 23, 2021

From IMV Inc.

Via Business Wire

IMV Inc. Announces Chief Financial Officer to Retire

November 22, 2021

From IMV Inc.

Via Business Wire

IMV Inc. Announces Third Quarter 2021 Financial and Operational Update

November 10, 2021

From IMV Inc.

Via Business Wire

Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting

November 09, 2021

From IMV Inc.

Via Business Wire

IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021

November 04, 2021

From IMV Inc.

Via Business Wire

Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

October 07, 2021

From IMV Inc.

Via Business Wire

Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting

October 01, 2021

From IMV Inc.

Via Business Wire

IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

September 30, 2021

From IMV Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021 ↗

September 22, 2021

Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE:

Via Benzinga

IMV Inc. to Present at Three Investor Conferences in September

September 01, 2021

From IMV Inc.

Via Business Wire

IMV Inc. (IMV) Q2 2021 Earnings Call Transcript ↗

August 11, 2021

IMV earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

IMV Inc. - Common Shares (NQ:IMV)

All News about IMV Inc. - Common Shares

Starting at $3.75/week.

Subscribe Today